Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts
Standard
Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. / Rostock, M; Huber, R; Greiner, T; Fritz, P; Scheer, R; Schueler, J; Fiebig, H H.
in: ANTICANCER RES, Jahrgang 25, Nr. 3B, 15.09.2005, S. 1969-75.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts
AU - Rostock, M
AU - Huber, R
AU - Greiner, T
AU - Fritz, P
AU - Scheer, R
AU - Schueler, J
AU - Fiebig, H H
PY - 2005/9/15
Y1 - 2005/9/15
N2 - BACKGROUND: In single case observations, tumour remissions after intratumoral injections of mistletoe extracts have been described.MATERIALS AND METHODS: We investigated the antitumour activity of intratumorally (i.t.)-injected lectin-rich mistletoe extract at different dosages and i.t.-injected mistletoe lectin I in comparison to intravenous (i.v.) Gemcitabine and i.t. treatment with placebo in a human pancreatic cancer xenograft.RESULTS: In a preliminary dose-response experiment, the most marked tumour inhibition was induced when mistletoe extract was given at 8 mg/kg body weight (BW) and mistletoe lectin I at 5.3 microg/kg BW. In a second experiment, bi-weekly i.t. injections of mistletoe extract over 8 weeks resulted in a very high antitumour activity with an optimal T/C value (=median relative tumour volume of the test group vs. the control) of 0.4% combined with 3/8 partial and 3/8 complete remissions. Gemcitabine was less active with 2/8 partial and 1/8 complete remissions and an optimal TIC of 4.6%.CONCLUSION: I.t.-injected lectin-rich mistletoe extract should be further evaluated in patients with inoperable locally advanced pancreatic cancer.
AB - BACKGROUND: In single case observations, tumour remissions after intratumoral injections of mistletoe extracts have been described.MATERIALS AND METHODS: We investigated the antitumour activity of intratumorally (i.t.)-injected lectin-rich mistletoe extract at different dosages and i.t.-injected mistletoe lectin I in comparison to intravenous (i.v.) Gemcitabine and i.t. treatment with placebo in a human pancreatic cancer xenograft.RESULTS: In a preliminary dose-response experiment, the most marked tumour inhibition was induced when mistletoe extract was given at 8 mg/kg body weight (BW) and mistletoe lectin I at 5.3 microg/kg BW. In a second experiment, bi-weekly i.t. injections of mistletoe extract over 8 weeks resulted in a very high antitumour activity with an optimal T/C value (=median relative tumour volume of the test group vs. the control) of 0.4% combined with 3/8 partial and 3/8 complete remissions. Gemcitabine was less active with 2/8 partial and 1/8 complete remissions and an optimal TIC of 4.6%.CONCLUSION: I.t.-injected lectin-rich mistletoe extract should be further evaluated in patients with inoperable locally advanced pancreatic cancer.
KW - Adenocarcinoma/drug therapy
KW - Animals
KW - Antimetabolites, Antineoplastic/pharmacology
KW - Antineoplastic Agents, Phytogenic/administration & dosage
KW - Cell Line, Tumor
KW - Deoxycytidine/analogs & derivatives
KW - Dose-Response Relationship, Drug
KW - Female
KW - Humans
KW - Injections, Intralesional
KW - Male
KW - Mice
KW - Mice, Nude
KW - Pancreatic Neoplasms/drug therapy
KW - Plant Preparations/administration & dosage
KW - Plant Proteins/administration & dosage
KW - Remission Induction
KW - Ribosome Inactivating Proteins, Type 2
KW - Toxins, Biological/administration & dosage
KW - Xenograft Model Antitumor Assays
M3 - SCORING: Journal article
C2 - 16158932
VL - 25
SP - 1969
EP - 1975
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 3B
ER -